ALDX Strangle Strategy
ALDX (Aldeyra The), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX (Aldeyra The) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $91.7M, a beta of 1.20 versus the broader market, a 52-week range of 1.07-6.175, average daily share volume of 1.4M, a public-listing history dating back to 2014, approximately 7 full-time employees. These structural characteristics shape how ALDX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.20 places ALDX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on ALDX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
ALDX snapshot
As of August 14, 2026, spot at $1.56, ATM IV 281.06%, IV rank 56.14%, expected move 80.58%. The strangle on ALDX below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on ALDX specifically: ALDX IV at 281.06% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 80.58% (roughly $1.26 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALDX expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALDX should anchor to the underlying notional of $1.56 per share and to the trader's directional view on ALDX stock.
ALDX strangle setup
The ALDX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALDX at $1.56 on that close, the first option leg uses a $1.64 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALDX chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALDX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.64 | N/A |
| Buy 1 | Put | $1.48 | N/A |
ALDX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ALDX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ALDX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ALDX
Strangles on ALDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALDX chain.
ALDX thesis for this strangle
The market-implied 1-standard-deviation range for ALDX extends from approximately $0.30 on the downside to $2.82 on the upside. A ALDX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ALDX IV rank near 56.14% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ALDX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ALDX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALDX-specific events.
ALDX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALDX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALDX alongside the broader basket even when ALDX-specific fundamentals are unchanged. Always rebuild the position from current ALDX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ALDX?
- A strangle on ALDX is the strangle strategy applied to ALDX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ALDX stock at $1.56 on the most recent close, the strikes shown on this page are snapped to the nearest listed ALDX chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ALDX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALDX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 281.06%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ALDX strangle?
- The breakeven for the ALDX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ALDX market-implied 1-standard-deviation expected move in the same options snapshot is approximately 80.58%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ALDX?
- Strangles on ALDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALDX chain.
- How does current ALDX implied volatility affect this strangle?
- ALDX ATM IV is at 281.06% with IV rank near 56.14%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.